SC Cracks Down on Unethical Pharma Marketing: New Panel Ordered!

The Supreme Court has taken a decisive step to address unethical practices in pharmaceutical marketing, directing the Union government to establish an expert committee. This landmark decision, issued on Thursday, October 8, 2026, comes in response to serious concerns about pharmaceutical companies allegedly influencing doctors through expensive gifts, overseas trips, and other incentives to promote specific drugs.

The Court, comprising Justices Vikram Nath and Sandeep Mehta, underscored the urgent need to strengthen the existing regulatory framework to ensure “ethical and affordable healthcare” for all citizens. The committee is tasked with a comprehensive examination of all issues related to unethical marketing, including the effectiveness of current regulations, oversight mechanisms, and measures to enhance transparency and accountability.

Its recommendations are expected to lead to a more robust regulatory framework, safeguarding the larger public interest.

This directive brings into sharp focus the long-standing debate over whether pharmaceutical marketing practices should be governed by a statutory regime, rather than the current voluntary framework. The Centre itself has acknowledged the challenges in using existing drug and essential commodities laws to provide statutory backing for such regulations.

The court highlighted that while the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024, has been largely effective, there's still a clear need to consider a statutory approach for pharmaceutical companies.

The petition, filed by the Federation of Medical and Sales Representatives’ Associations of India (FMRAI) and others, argued that such aggressive marketing tactics can have severe public health consequences, including adverse drug reactions and the critical issue of antimicrobial resistance. Justice Mehta, authoring the order, noted that the existing framework has proven ineffective in curbing these practices, emphasizing that the efficacy of regulation must be judged by its implementation, not just its existence.

The Supreme Court has given the Union government two weeks to constitute the expert committee, which must then submit its recommendations within two months of its first meeting. Following this, the government is required to make a “reasoned decision” on the recommendations and file a compliance affidavit within two weeks.

The matter is scheduled for further hearing on January 29, 2027, to assess the progress.

The Court clarified its role is not to formulate policy but to facilitate a “meaningful and effective consultative process,” balancing industry interests with public health.

#PharmaEthics #SupremeCourt #HealthcareReform #MedicalRegulation